(Q46635646)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23484530%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

title

Perspectives on designs of antiandrogens for prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23484530%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

author

Eva Estébanez-Perpiñá

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23484530%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

3

Robert J Fletterick

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23484530%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

author name string

Natalia Jouravel

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23484530%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

language of work or name

English

0 references

publication date

1 October 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23484530%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Discovery

25 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23484530%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23484530%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23484530%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

page(s)

1341-1355

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23484530%20AND%20SRC:MED&resulttype=core&format=json

Cloning of Human Androgen Receptor Complementary DNA and Localization to the X Chromosome

25 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Recent advances in androgen receptor action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Characterization and expression of a cDNA encoding the human androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Domains of the Human Androgen Receptor Involved in Steroid Binding, Transcriptional Activation, and Subcellular Localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Identification of two transcription activation units in the N-terminal domain of the human androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Prevention of hormone-related cancers: prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Combinatorial androgen receptor targeted therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Distinct steady-state nuclear receptor coregulator complexes exist in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Molecular chaperones throughout the life cycle of the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

C-terminal Hsp-interacting protein slows androgen receptor synthesis and reduces its rate of degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

The nuclear receptor ligand-binding domain: structure and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Different positioning of the ligand-binding domain helix 12 and the F domain of the estrogen receptor accounts for functional differences between agonists and antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Finding specificity within a conserved interaction site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Androgen receptor corepressors and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Domain Interactions between Coregulator ARA70and the Androgen Receptor (AR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

The expanding cosmos of nuclear receptor coactivators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Androgen receptor coregulators and their involvement in the development and progression of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Expression of androgen receptor coregulators in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Formation of the androgen receptor transcription complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

A role of the amino-terminal (N) and carboxyl-terminal (C) interaction in binding of androgen receptor to chromatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Post-translational modifications of steroid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Androgen receptor acetylation site mutations cause trafficking defects, misfolding, and aggregation similar to expanded glutamine tracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Drug insight: role of the androgen receptor in the development and progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Androgen receptor mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Mutation of the androgen receptor causes oncogenic transformation of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Molecular basis of androgen insensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Novel and recurrent mutations in patients with androgen insensitivity syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Androgen receptor mutations causing human androgen insensitivity syndromes show a key role of residue M807 in Helix 8-Helix 10 interactions and in receptor ligand-binding domain stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Who is the average patient presenting with prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

A molecular correlate to the Gleason grading system for prostate adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Androgen axis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Mechanistic concepts in androgen-dependence of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Androgen receptors in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Androgen receptor action in hormone-dependent and recurrent prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Persistent intraprostatic androgen concentrations after medical castration in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Structural basis of androgen receptor binding to selective androgen response elements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Structural basis for accommodation of nonsteroidal ligands in the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Structural basis for antagonism and resistance of bicalutamide in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Circumventing anti-androgen resistance by molecular design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Mifepristone (RU486): a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Structural insights into the mode of action of a pure antiestrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Nuclear receptor antagonists designed based on the helix-folding inhibition hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Growth inhibition of androgen-insensitive human prostate carcinoma cells by a 19-norsteroid derivative agent, mifepristone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Synthesis of C-11 modified mifepristone analog libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Androgen receptor-cofactor interactions as targets for new drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Recognition and accommodation at the androgen receptor coactivator binding interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Androgen receptor decoy molecules block the growth of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341

Phosphorylation of androgen receptor isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.10.1341